Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Pfizer shares have gained ground since a report over the weekend said that activist investor ...

Goldman Sachs hosted a meeting with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025). The analyst maintains the Buy rating with a price target ...

Pfizer’s PFE $13.7 billion in revenue (an 8% decline) and adjusted diluted EPS of $0.92 (12% growth) allowed the firm to maintain its full-year guidance of $61 billion-$64 billion in revenue and $2.80 ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer’s future growth to ...

Pfizer said on ​Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a ...

Why Johnson & Johnson’s stability, dividend growth, and buybacks may beat Pfizer’s low valuation and high yield. Read the ...